Assouline SE et al. Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: Updated clinical experience from a phase I dose-escalation trial. ASH 2020;Abstract 702.
Budde E et al. Preliminary results of a Phase 1 dose escalation study of the first-in-class IgM based bispecific antibody Igm-2323 (anti-CD20 x anti-CD3) in patients with advanced B-cell malignancies. ASH 2020;Abstract 1142.
Fitzgerald L et al. Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy. ASCO 2020;Abstract 8039.
Jain P et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol 2021;192(2):e38-42. Abstract
Jain P et al. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 2021;96(5):E137-40. Abstract
Munoz J et al. Copanlisib for the treatment of malignant lymphoma: Clinical experience and future perspectives. Target Oncol 2021;16(3):295-308. Abstract
Nastoupil LJ. When to use targeted therapy for the treatment of follicular lymphoma. Curr Hematol Malig Rep 2021;16(1):45-51. Abstract
Scholz CW et al. A phase III trial (GO42909) evaluating mosunetuzumab in combination with lenalidomide (M-Len) versus rituximab-lenalidomide (R-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL). EHA 2021;Abstract PB1565.
Spiegel JY et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 2021;137(13):1832-5. Abstract
Strati P et al. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood 2021;137(8):1124-9. Abstract
Strati P et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 2021;137(23):3272-6. Abstract
Xie J et al. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era. Curr Med Res Opin 2021;37(10):1789-98. Abstract